The drug industry and 340B program advocates offered mixed reactions Monday to a key senator’s latest inquiries into drugmakers’ contract pharmacy restrictions as part of an ongoing congressional probe of the drug pricing program.

Sen. Cassidy’s Letters to Drug Manufacturers Welcomed by Drug Industry Trade Group, Draw Skepticism from 340B Provider Advocates

September 24, 2024 Bella Czajkowski, National Correspondent & Shannon Young, Associate Editor/Senior Writer Views

The drug industry and 340B program advocates offered mixed reactions Monday to a key senator’s latest inquiries into drugmakers’ contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Sen. Cassidy’s Letters to Drug Manufacturers Welcomed by Drug Industry Trade Group, Draw Skepticism from 340B Provider Advocates

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Bella Czajkowski and Shannon Young

Sen. Cassidy’s Letters to Drug Manufacturers Welcomed by Drug Industry Trade Group, Draw Skepticism from 340B Provider Advocates

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Bella Czajkowski and Shannon Young

Site Footer Live